MONICA NUCKOLLS: Open Payments
NPI 1871375543 · SIOUX CITY, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,978 in 223 payments from 14 companies in 2025. Trend: 2023 $43 · 2024 $1,074 · 2025 $2,978
Food & beverage: $2,978
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 43 | $436 |
| Otsuka America Pharmaceutical, Inc. | 22 | $328 |
| Vanda Pharmaceuticals Inc. | 23 | $322 |
| Neurocrine BioSciences, Inc. | 20 | $266 |
| Lundbeck LLC | 15 | $264 |
| Teva Pharmaceuticals USA, Inc. | 13 | $220 |
| Corium, LLC | 12 | $212 |
| Alkermes, Inc. | 14 | $200 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $192 |
| E.R. Squibb & Sons, L.L.C. | 11 | $189 |
Products named: REXULTI, VRAYLAR, INGREZZA, Azstarys, ARISTADA, CAPLYTA, COBENFY, HETLIOZ.
Industry payments across IA — which companies pay providers there.
